Skip to main content
SpringerLink
Log in

Management of Chronic Obstructive Pulmonary Disease

  • Living reference work entry
  • First Online:
Handbook of Healthcare in the Arab World

  • 213 Accesses

Abstract

The World Health Organization (WHO) revealed that the fourth leading cause of chronic morbidity and mortality worldwide is chronic obstructive pulmonary disease (COPD). There is increased awareness of COPD by the medical community. However, it remains a major public health problem because patients and public health and government officials are unaware of it or ignore it.

The important fact to address is that this COPD epidemic is increasing in the Arab world due to smoking. Despite persistent increases in the prevalence and incidence of COPD, health-care professionals worldwide underdiagnose and undertreat the disease, and for many patients the disease is mostly unrecognized. The purpose of this chapter is to describe factors that lead to increase in the disease prevalence and to highlight the issues related to under management of COPD.

High-risk individuals, such as long-term smokers, often ignore the symptoms of chronic pulmonary disease until disability occurs. Signs and symptoms are often insidious in nature and play an important role in preventing early diagnosis and treatment of chronic pulmonary diseases. Patients having difficulty breathing with shortness of breath, cough, sputum production, and nose or throat irritations that do not subside within 2 weeks need medical attention. The importance of increasing public awareness of the consequences of smoking and the risk of COPD is imperative.

The definition, signs and symptoms, major risk factors associated with the onset of COPD, and the treatment plans for patients with stable COPD and for those with an acute exacerbation are described in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Adeloye D, Chua S, Lee CW et al (2015) Global and regional estimates of COPD prevalence: systemic review and meta-analysis. J Glob Health 5:020415

    Article  Google Scholar 

  • Al Ghobain M, Alhamad EH, Alorainy HS, Al Kassimi F, Lababidi H, Al-Hajjaj MS (2015) The prevalence of chronic obstructive pulmonary disease in Riyadh, Saudi Arabia: a BOLD study. Int J Tuberc Lung Dis 9:1252–1257

    Article  Google Scholar 

  • Albert RK, Connett J, Bailey WC et al (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365(8):689–698

    Article  CAS  Google Scholar 

  • Al-Fayez SF, Salleh M, Ardawi M, AZahran FM (1988) Effects of sheesha and cigarette smoking on pulmonary function of Saudi males and females. Trop Geogr Med 40(2):115–123

    CAS  PubMed  Google Scholar 

  • American Thoracic Society (1995) COPD: definitions, epidemiology, pathophysiology, diagnosis and staging. Am J Respir Crit Care Med 152(5, Pt 1):1713–1735

    Article  Google Scholar 

  • Banasik J (2001) Diagnosing alpha 1-antitrypsin deficiency. Nurse Pract 26(1):58–62

    CAS  PubMed  Google Scholar 

  • Barnes P (1995) Bronchodilators: basic pharmacology. In: Calverley PMA, Pride NB (eds) Chronic obstructive pulmonary disease. Chapman and Hall, London, pp 391–417

    Chapter  Google Scholar 

  • Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54:581–586

    Article  CAS  Google Scholar 

  • Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B, Miravitlles M (2006) Estimated numbers and prevalence of PI∗S and PI∗Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 27(1):77–84

    Article  CAS  Google Scholar 

  • Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320(7245):1297–1303

    Article  CAS  Google Scholar 

  • Cahill K, Stevens S, Perera R, Lancaster T (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev (5):CD009329

    Google Scholar 

  • Calverley PM, Anderson JA, Celli B et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356(8):775–789

    Article  CAS  Google Scholar 

  • Calverley PM, Rabe KF, Goehring UM et al (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691):685–694

    Article  CAS  Google Scholar 

  • Carson AR, Hieber KV (2001) Adult pediatric patients. Am J Nurse 101(3):46–55

    Article  CAS  Google Scholar 

  • Cazzola M, Molimard M (2010) The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 23(4):257–267

    Article  CAS  Google Scholar 

  • Centers for Disease Control and Prevention (2002) Surveillance summaries. MMWR 2002:51(No. SS-6)

    Google Scholar 

  • Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC et al (2001) Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 18(1):85–92

    Article  CAS  Google Scholar 

  • Cranston JM, Crockett AJ, Moss JR, Alpers JH (2005) Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (4):CD001744

    Google Scholar 

  • Datta D, Vitale A, Lahiri B, ZuWallack R (2003) An evaluation of nebulized levalbuterol in stable COPD. Chest 124(3):844–849

    Article  CAS  Google Scholar 

  • Decramer ML, Chapman KR, Dahl R et al (2013) Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 1:524–533

    Article  CAS  Google Scholar 

  • Effing TW, Vercoulen JH, Bourbeau J et al (2016) Definition of a COPD self-management intervention: International Expert Group consensus. Eur Respir J 48(1):46–54

    Article  Google Scholar 

  • Ferreira IM, Brooks D, White J, Goldstein R (2012) Nutritional supplementation for stable COPD. Cochrane Database Syst Rev (12):CD000998

    Google Scholar 

  • Festic E, Scanlon PD (2015) Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease: a double effect of inhaled corticosteroids? Am J Respir Crit Care Med 191:141–148

    Article  Google Scholar 

  • Francis RS, May JR, Spicer CC (1961) Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or intermittently for exacerbations. A report to the Research Committee of the British Tuberculosis Association by its Bronchitis Subcommittee. Br Med J 2(5258):979–985

    Article  CAS  Google Scholar 

  • Global Initiative for Chronic Obstructive Lung Disease (2017) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd. Accessed 10 Sept 2017

  • Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF (1989) Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 139(5):1188–1191

    Article  CAS  Google Scholar 

  • Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S (1998) Inhalation by nebulization of albuterol- ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 65(5):354–362

    Article  CAS  Google Scholar 

  • Han MK, Tayob N, Murray S et al (2014) Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 189:1503–1508

    Article  CAS  Google Scholar 

  • Hnizdo E, Sullivan PA, Bang KM, Wagner G (2002) Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 156(8):738–746

    Article  Google Scholar 

  • Hu G, Zhou Y, Tian J et al (2010) Risk of COPD from exposure to biomass smoke: a meta-analysis. Chest 138:20–31

    Article  Google Scholar 

  • Jindal SK, Aggarwal AN, Chaudhry K, Chhabra SK, D’Souza GA, Gupta D et al (2006) A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci 48(1):23–29

    CAS  PubMed  Google Scholar 

  • Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A (2006) Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 173(12):1316–1325

    Article  Google Scholar 

  • Jones P, Tabberer M, Chen WH (2011) Creating scenarios of the impact of COPD and their relationship to COPD assessment test (CATTM) scores. BMC Pul Med 11:42

    Article  Google Scholar 

  • Jones PW, Adamek L, Nadeau G, Banik N (2013) Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J 42:647–654

    Article  Google Scholar 

  • Karner C, Chong J, Poole P (2014) Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (7):CD009285

    Google Scholar 

  • Kesten S, Jara M, Wentworth C, Lanes S (2006) Pooled clinical trial analysis of tiotropium safety. Chest 130(6):1695–1703

    Article  CAS  Google Scholar 

  • Kesten S, Casaburi R, Kukafka D, Cooper CB (2008) Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 3(1):127–136

    Article  CAS  Google Scholar 

  • Kew KM, Mavergames C, Walters JA (2013) Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (10):CD010177

    Google Scholar 

  • Khattab A, Javaid A, Iraqi G et al (2012) Smoking habits in the Middle East and North Africa: results of the BREATHE study. Respir Med 106(Suppl 2):S16–S24

    Article  Google Scholar 

  • Khdour MR, Kidney JC, Smyth BM, McElnay JC (2009) Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol 68(4):588–598

    Article  Google Scholar 

  • Khdour MR, Agus AM, Kidney JC, Smyth BM, Elnay JC, Crealey GE (2011) Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm 33(4):665–673

    Article  Google Scholar 

  • Konzem SL, Stratton MA (2002) Chronic obstructive lung disease. In: DiPiro JT, Talbert RL, Yee GC et al (eds) Pharmacotherapy: a pathophysiologic approach, 5th edn. McGraw-Hill, New York, pp 511–529

    Google Scholar 

  • Lee SH, Goswami S, Grudo A et al (2007) Anti-elastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13(5):567–569

    Article  CAS  Google Scholar 

  • Lindenauer PK, Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Hill NS (2014) Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease. JAMA Intern Med 174(12):1982–1993

    Article  Google Scholar 

  • Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS et al (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27(2):397–412

    Article  CAS  Google Scholar 

  • Marchetti N, Criner GJ (2015) Surgical approaches to treating emphysema: lung volume reduction surgery, bullectomy, and lung transplantation. Semin Respir Crit Care Med 36(4):592–608

    Article  Google Scholar 

  • Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR (1997) Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 155(6):1984–1990

    Article  CAS  Google Scholar 

  • Matheson MC, Benke G, Raven J, Sim MR, Kromhout H, Vermeulen R et al (2005) Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax 60(8):645–651

    Article  CAS  Google Scholar 

  • McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y (2015) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2):CD003793

    Google Scholar 

  • McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ (1993) Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 48(3):227–223

    Article  CAS  Google Scholar 

  • McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P (2014) Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev (12):CD010216

    Google Scholar 

  • Melani AS (2015) Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol 8(4):479–501

    Article  CAS  Google Scholar 

  • Mirza S, Clay RD, Koslow MA, Scanlon PD (2018) COPD guidelines: a review of the 2018 GOLD report. Mayo Clin Proc 93(10):1488–1502

    Article  Google Scholar 

  • Murphy KR (2004) Asthma: helping patients breathe easier. Nurs Pract 29(10):38–55

    Article  Google Scholar 

  • Nannini LJ, Poole P, Milan SJ, Kesterton A (2013) Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (8):CD006826

    Google Scholar 

  • Ni W, Shao X, Cai X et al (2015) Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One 10(3):e0121257

    Article  Google Scholar 

  • Nishimura K, Izumi T, Tsukino M, Oga T (2002) Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121:1434–1440

    Article  Google Scholar 

  • Okuyemi KS, Nollen NL, Ahluwalia JS (2006) Interventions to facilitate smoking cessation. Am Fam Physician 74(2):262–271

    PubMed  Google Scholar 

  • Pelkonen M, Tukiainen H, Tervahauta M et al (2000) Pulmonary function, smoking cessation and 30-year mortality in middle aged Finnish men. Thorax 55:746–750

    Article  CAS  Google Scholar 

  • Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163(1):53–67

    Article  CAS  Google Scholar 

  • Scanlon PD, Connett JE, Waller LA et al (2000) Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am J Respir Crit Care Med 161:381–390

    Article  CAS  Google Scholar 

  • Singh D (2015) New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol 79:695–708

    Article  CAS  Google Scholar 

  • Singh D, Papi A, Corradi M et al (2016) Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388:963–973

    Article  CAS  Google Scholar 

  • Soriano JR, Maier WC, Egger P, Visick G, Thakrar B, Sykes J et al (2000) Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 55:789–794

    Article  CAS  Google Scholar 

  • Spruit MA, Singh SJ, Garvey C et al (2013) An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188(8):e13–e64

    Article  Google Scholar 

  • Stoller JK, Aboussouan LS (2005) Alpha1-antitrypsin deficiency. Lancet 365(9478):2225–2236

    Article  CAS  Google Scholar 

  • Sze MA, Dimitriu PA, Suzuki M et al (2015) Host response to the lung microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192(4):438–445

    Article  CAS  Google Scholar 

  • Tageldin MA, Nafti S, Khan JA, Nejjari C, Beji M, Mahboub B, Obeidat NM, Uzaslan E, Sayiner A, Wali S, Rashid N (2012) Distribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE study. Respir Med 106:S25–S32

    Article  Google Scholar 

  • Tashkin D, Kanner R, Bailey W et al (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357(9268):1571–1575

    Article  CAS  Google Scholar 

  • Tashkin DP, Pearle J, Iezzoni D, Varghese ST (2009) Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 6(1):17–25

    Article  Google Scholar 

  • Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC (2011) Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 139(3):591–599

    Article  Google Scholar 

  • Trupin L, Earnest G, San Pedro M, Balmes JR, Eisner MD, Yelin E et al (2003) The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 22(3):462–469

    Article  CAS  Google Scholar 

  • Turato G, Zuin R, Saetta M (2001) Pathogenesis and pathology of COPD. Respiration 68(2):117–128

    Article  CAS  Google Scholar 

  • Uzaslan E, Mahboub B, Beji M, Nejjari C, Tageldin MA, Khan JA, Nafti S, Obeidat NM, Sayiner A, Wali S, Rashid N (2012) The burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE study. Respir Med 106:S45–S59

    Article  Google Scholar 

  • van der Meer RM, Wagena EJ, Ostelo RW, Jacobs JE, van Schayck CP (2003) Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2):CD002999

    Google Scholar 

  • Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE (1988) High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 138(4):850–855

    Article  CAS  Google Scholar 

  • Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 353(9167):1819–1823

    Article  CAS  Google Scholar 

  • Vogelmeier C, Hederer B, Glaab T et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093–1103

    Article  CAS  Google Scholar 

  • Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM (2016) American Thoracic Society/European Respiratory Society Task Force on Policy in pulmonary rehabilitation. Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement. Eur Respir J 47(5):1336–1341

    Article  Google Scholar 

  • Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH (2014) Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (9):CD001288

    Google Scholar 

  • Warwick H, Doig A (2004) Smoke the killer in the kitchen: indoor air pollution in developing countries. ITDG Publishing, London. http://www.itdgpublishing.org.uk

  • Welte T, Miravitlles M, Hernandez P et al (2009) Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180(8):741–750

    Article  CAS  Google Scholar 

  • WHO (2004) http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed 10 Sept 2017

  • WHO (2016) http://www.who.int/healthinfo/paper36.pdf. Accessed 12 Oct 2017

  • Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S (2004) Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 125(6):2011–2020

    Article  Google Scholar 

  • World Health Organization (2016) Chronic obstructive pulmonary disease (COPD). Available from: www.who.int/mediacentre/factsheets/fs315/en. Accessed Dec 2017

  • Yang IA, Clarke MS, Sim EH, Fong KM (2012) Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (7):CD002991

    Google Scholar 

  • Zacarias EC, Castro AA, Cendon S (2007) Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. J Bras Pneumol 33(2):152–160

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Al-Quds University, Jerusalem, Palestine

    Maher Khdour

  2. Faculty of Medicine, Al-Quds University, Jerusalem, Palestine

    Hussein Hallak & Hani Abdeen

Authors
  1. Maher Khdour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hussein Hallak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hani Abdeen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maher Khdour .

Editor information

Editors and Affiliations

  1. Dept. Pharmacology Therapeutics, University of British Colombia Dept. Pharmacology Therapeutics, VANCOUVER, BC, Canada

    Ismail Laher

Section Editor information

  1. Pulmonary, Tishreen University And Syrian Private University, Lattakia, Syria

    Yousser Mohammad

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Khdour, M., Hallak, H., Abdeen, H. (2019). Management of Chronic Obstructive Pulmonary Disease. In: Laher, I. (eds) Handbook of Healthcare in the Arab World. Springer, Cham. https://doi.org/10.1007/978-3-319-74365-3_128-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74365-3_128-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74365-3

  • Online ISBN: 978-3-319-74365-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation